MARKET

DMAC

DMAC

Diamedica Therapeutics Inc
NASDAQ
4.000
-0.230
-5.44%
After Hours: 4.000 0 0.00% 16:05 05/05 EDT
OPEN
4.280
PREV CLOSE
4.230
HIGH
4.630
LOW
4.000
VOLUME
50.41K
TURNOVER
--
52 WEEK HIGH
6.82
52 WEEK LOW
2.140
MARKET CAP
171.42M
P/E (TTM)
-6.6116
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at DMAC last week (0428-0502)?
Weekly Report · 12h ago
Weekly Report: what happened at DMAC last week (0421-0425)?
Weekly Report · 04/28 09:52
Weekly Report: what happened at DMAC last week (0414-0418)?
Weekly Report · 04/21 09:51
DiaMedica Therapeutics: Stroke Developer With Low Cash Reserve
Seeking Alpha · 04/16 00:54
Why Ericsson Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Benzinga · 04/15 09:19
Weekly Report: what happened at DMAC last week (0407-0411)?
Weekly Report · 04/14 09:48
Weekly Report: what happened at DMAC last week (0331-0404)?
Weekly Report · 04/07 09:47
Weekly Report: what happened at DMAC last week (0324-0328)?
Weekly Report · 03/31 09:51
More
About DMAC
More
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.
Recently
Symbol
Price
%Change

Webull offers DiaMedica Therapeutics Inc stock information, including NASDAQ: DMAC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DMAC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DMAC stock methods without spending real money on the virtual paper trading platform.